These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19009938)

  • 1. [Benefit assessment in special situations--rare diseases].
    Windeler J; Lange S
    Z Evid Fortbild Qual Gesundhwes; 2008; 102(1):25-30. PubMed ID: 19009938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of orphan medicines.
    Buckley BM
    Lancet; 2008 Jun; 371(9629):2051-5. PubMed ID: 18555919
    [No Abstract]   [Full Text] [Related]  

  • 4. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group.
    Richter T; Nestler-Parr S; Babela R; Khan ZM; Tesoro T; Molsen E; Hughes DA;
    Value Health; 2015 Sep; 18(6):906-14. PubMed ID: 26409619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical considerations in orphan drug approval and use.
    Kesselheim AS
    Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The pharmacist, rare diseases and orphan medicines].
    Nagore Induráin C; Lacalle E; Arteche L
    An Sist Sanit Navar; 2008; 31 Suppl 2():127-43. PubMed ID: 18953376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rare diseases, definitions and epidemiology].
    Donnart A; Viollet V; Roinet-Tournay M
    Soins Pediatr Pueric; 2013; (274):14-6. PubMed ID: 24228328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM; Rask-Andersen M; Schiöth HB
    Trends Pharmacol Sci; 2018 Jun; 39(6):525-535. PubMed ID: 29779531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the use of orphan drugs in clinical practice.
    Hulton SA; Greener M
    Hosp Med; 2004 Jul; 65(7):400-3. PubMed ID: 15287343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Don't Do Different Things…Do Things Differently! Drug Development in Rare Diseases.
    Rudek MA; Korth-Bradley JM
    Clin Pharmacol Ther; 2016 Oct; 100(4):333-5. PubMed ID: 27393720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orphan drug development in China: progress and challenges.
    Zhang S; Chen L; Zhang Z; Zhao Y
    Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
    [No Abstract]   [Full Text] [Related]  

  • 14. Brexit and rare diseases: big risk, bigger opportunity?
    Hyry HI; Cox TM; Roos JC
    Curr Med Res Opin; 2017 Apr; 33(4):783-784. PubMed ID: 28100081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new toolkit for conducting clinical trials in rare disorders: will this dog hunt?
    Peterson RG; Macleod SM; Klein AV
    J Popul Ther Clin Pharmacol; 2014; 21(1):e79-80. PubMed ID: 24671905
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
    Picavet E; Cassiman D; Pinxten W; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A methodological framework for drug development in rare diseases.
    Nony P; Kurbatova P; Bajard A; Malik S; Castellan C; Chabaud S; Volpert V; Eymard N; Kassai B; Cornu C; ;
    Orphanet J Rare Dis; 2014 Nov; 9():164. PubMed ID: 25774598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of patient advocates in rare cancers: opportunities and challenges.
    Gonzato O; Gronchi A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):1-3. PubMed ID: 30227750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.